Showing results (1-10 of 59) with videos related to
Sort By:
Pageof 6
Journal of Medical Economics|June 5, 2018
Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorderArpamas Seetasith, Mallik Greene, Ann Hartry, et al.International Journal of Nephrology|April 11, 2014
Evaluation of the Prevalence of Chronic Kidney Disease and Rates of Oral Antidiabetic Prescribing in Accordance with Guidelines and Manufacturer Recommendations in Type 2 Diabetic Patients within a Long-Term Care SettingNing Wu, Xia Yu, Mallik Greene, et al.Clinicoeconomics and Outcomes Research : CEOR|December 12, 2019
Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive DisorderArpamas Seetasith, Mallik Greene, Ann Hartry, et al.Current Medical Research and Opinion|April 13, 2026
Multi-target stool DNA test adherence among individuals screened for colorectal cancer through the US Defense Health AgencyShrey Gohil, Mohamed Omar, Jordan Karlitz, et al.Journal of Affective Disorders|September 30, 2017
The economic burden of bipolar I disorder in the United States in 2015Martin Cloutier, Mallik Greene, Annie Guerin, et al.Current Medical Research and Opinion|October 17, 2018
Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centersMallik Greene, Chakkarin Burudpakdee, Arpamas Seetasith, et al.Journal of Comparative Effectiveness Research|April 26, 2018
Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USAMargarida Augusto, Mallik Greene, Maëlys Touya, et al.Journal of Comparative Effectiveness Research|August 22, 2018
Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorderTingjian Yan, Mallik Greene, Eunice Chang, et al.Journal of Comparative Effectiveness Research|April 26, 2018
Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USAMargarida Augusto, Mallik Greene, Maëlys Touya, et al.Journal of Medical Economics|September 7, 2018
A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United StatesMartin Cloutier, Mallik Greene, Maëlys Touya, et al.Pageof 6